NeuroStar has the largest clinical data set of any TMS treatment. Clinical studies with over 900 people have shown that NeuroStar may help achieve remission for people living with depression. NeuroStar TMS is the only TMS system with the durability of its effects established over 12 months.
In a trial with physician directed standard of care, meaning Neurostar TMS Therapy could be used in conjunction with antidepressants as needed, patients who had received treatment then reported their symptom levels at 3, 6, 9 and 12 months to determine the durability of their treatments. By the end of the 12-month period, 2 out of 3 patients who had either responded or completely remitted after TMS treatment remained at the symptom levels they reported at the end of the treatment phase. After the end of the treatment period, only 1 in 3 patients needed to come back for maintenance TMS sessions, or ‘reintroduction’ during this 12-month period.